mefloquine hydrochloride and loperamide

mefloquine hydrochloride has been researched along with loperamide in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (25.00)29.6817
2010's0 (0.00)24.3611
2020's3 (75.00)2.80

Authors

AuthorsStudies
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M1
Carrupt, PA; Crivori, P; Cruciani, G; Testa, B1
Byun, SY; Choi, I; Jeon, S; Kim, S; Ko, M; Lee, J; Park, S; Shum, D1
Easwaran, M; Manickam, M; Pillaiyar, T; Wendt, LL1

Reviews

1 review(s) available for mefloquine hydrochloride and loperamide

ArticleYear
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.
    Medicinal research reviews, 2021, Volume: 41, Issue:1

    Topics: Antiviral Agents; Chemistry, Pharmaceutical; COVID-19; Disease Outbreaks; Drug Repositioning; Humans; Virus Internalization

2021

Other Studies

3 other study(ies) available for mefloquine hydrochloride and loperamide

ArticleYear
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
    Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3

    Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries

2023
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
    Journal of medicinal chemistry, 2000, Jun-01, Volume: 43, Issue:11

    Topics: Blood-Brain Barrier; Databases, Factual; Models, Chemical; Molecular Conformation; Multivariate Analysis; Permeability; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship

2000
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
    Antimicrobial agents and chemotherapy, 2020, 06-23, Volume: 64, Issue:7

    Topics: Animals; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Coronavirus Infections; COVID-19; Drug Evaluation, Preclinical; Drug Repositioning; Humans; Niclosamide; Pandemics; Pneumonia, Viral; Pregnenediones; SARS-CoV-2; Vero Cells

2020